Clinical Trial Detail

NCT ID NCT03816345
Title Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

stomach cancer

Hodgkin's lymphoma

lung non-small cell carcinoma

melanoma

renal cell carcinoma

lung small cell carcinoma

urinary bladder cancer

head and neck cancer

hepatocellular carcinoma

Merkel cell carcinoma

cervical cancer

Advanced Solid Tumor

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.